Intas Pharmaceuticals Gets CDSCO Panel Nod to Study Trastuzumab Emtansine in Metastatic Breast Cancer
New Delhi: In a significant development, Intas Pharmaceuticals has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III study to evaluate the efficacy, …